Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to $91.0 million.

  • Denali Therapeutics' Cash & Equivalents rose 0.36% to $91.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.0 million, marking a year-over-year increase of 0.36%. This contributed to the annual value of $175.0 million for FY2024, which is 37.65% up from last year.
  • As of Q3 2025, Denali Therapeutics' Cash & Equivalents stood at $91.0 million, which was down 35.58% from $141.2 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Cash & Equivalents peaked at $485.7 million during Q2 2021, and registered a low of $56.9 million during Q1 2025.
  • Over the past 3 years, Denali Therapeutics' median Cash & Equivalents value was $91.0 million (recorded in 2025), while the average stood at $105.9 million.
  • In the last 5 years, Denali Therapeutics' Cash & Equivalents soared by 254.04% in 2021 and then plummeted by 75.89% in 2022.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Cash & Equivalents stood at $293.5 million in 2021, then declined by 25.70% to $218.0 million in 2022, then slumped by 41.71% to $127.1 million in 2023, then soared by 37.65% to $175.0 million in 2024, then climbed by 0.36% to $91.0 million in 2025.
  • Its last three reported values are $91.0 million in Q3 2025, $141.2 million for Q2 2025, and $56.9 million during Q1 2025.